País: Malta
Língua: inglês
Origem: Malta Medicines Authority
ZOLEDRONIC ACID, MONOHYDRATE
Ibigen S.r.L Via Fossignano, 2, 04011 Aprilia (LT), Italy
M05BA08
ZOLEDRONIC ACID MONOHYDRATE 4 mg/ml
CONCENTRATE FOR SOLUTION FOR INFUSION
ZOLEDRONIC ACID MONOHYDRATE 4 mg/ml
POM
DRUGS FOR TREATMENT OF BONE DISEASES
Withdrawn
2013-01-16
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER ZOLEDRONIC ACID IBIGEN 4 MG/5 ML CONCENTRATE FOR SOLUTION FOR INFUSION Zoledronic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU • Keep this leaflet. You may need to read it again • If you have any further questions, ask your doctor, nurse or pharmacist • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET 1. What Zoledronic Acid is and what it is used for 2. What you need to know before you are given Zoledronic Acid 3. How Zoledronic Acid is used 4. Possible side effects 5. How to store Zoledronic Acid 6. Contents of the pack and other information 1. WHAT ZOLEDRONIC ACID IS AND WHAT IT IS USED FOR The active substance in Zoledronic Acid Ibigen is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used: • TO PREVENT BONE COMPLICATIONS, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone) • TO REDUCE THE AMOUNT OF CALCIUM in the blood in cases where it is too high due to the presence of a tumour in adult patients. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH) 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ZOLEDRONIC ACID Follow carefully all instructions given to you by your doctor. Your doctor will carry out blood tests before you start treatment with Zoledronic Acid and will check your response to treatment at regular intervals. YOU SHOULD NOT BE GIVEN ZOLEDRONIC ACID: • if you are breast-feeding • if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which Zoledronic Acid belongs), or any of the other ingredi Leia o documento completo
Page 1 of 23 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Zoledronic Acid Ibigen 4 mg/5 ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial with 5 ml concentrate contains 4 mg zoledronic acid (anhydrous), corresponding to 4.66 mg zoledronic acid hemypentahydrate. One ml concentrate contains zoledronic acid (as hemypentahydrate) corresponding to 0.8 mg zoledronic acid (anhydrous). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion Clear and colourless solution 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone • Treatment of adult patients with tumour-induced hypercalcaemia (TIH) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zoledronic Acid Ibigen must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with Zoledronic Acid Ibigen should be given the package leaflet and the patient reminder card. Posology Prevention of skeletal related events in patients with advanced malignancies involving bone _ _ _Adults and older people _ The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg Zoledronic Acid Ibigen every 3 to 4 weeks. Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily. The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months. Page 2 of 23 Treatment of TIH _Adults and older people _ The recommended dose in hypercalcaemia (albumin-corrected serum calcium ≥ 12.0 mg/dl or 3.0 mmol/l) is 4 mg Zoledronic Acid Ibigen. Renal impairment _TIH: _ Zoledronic Acid Leia o documento completo